




LUNG-MAP


S1400 Lung-Master Protocol

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

S1400 Master Protocol Unique Private-Public Partnerships with NCTN



Significantly mutated genes in lung SQCC



The Cancer Genome Atlas (TCGA: Nature 489:519; 2012)
 178 lung SQCC provided landscape of genomic and epigenomic alterations with a potential therapeutic target, offering new avenues of investigation for the treatment of SQCC

Metastatic Squamous NSCLC: Design Parameters

Principle Eligibility Requirements:

- Pathologically confirmed squamous
- Incurable Stage IV
- Failed at least one front-line chemotherapy
- Measurable Disease
- PS \leq 2

Statistical Design:

- Accrual rate: 500-1000 patients per year
- Phase II/ III design

Pre-Screening Registration

Screening Registration

Common Broad Platform CLIA Biomarker Profiling

Progression

Sub-study Assignment

If known positive biomarker

**If not eligible for
Biomarker driven
sub-study**

1400A (Immunotherapies)

S1400B

Target PI3K

S1400C

Target CDK4/6

S1400D

Target FGFR

**S1400B
Arm 1
GDC-0032**

**S1400B
Arm 2
Docetaxel**

**S1400C
Arm 1
Palbociclib**

**S1400C
Arm 2
Docetaxel**

**S1400D
Arm 1
AZD4547**

**S1400D
Arm 2
Docetaxel**

Tissue Requirements

1. **Tissue block (preferred) or at least 12 (4-5) -micron unstained slides (20 slides are strongly recommended).**
 - Tissue must contain at least 20% viable tumor cells
2. **Hematoxylin-eosin (H&E)-stained slide or Aperio H&E-stained slide**
3. **Local pathology report from initial diagnosis**
4. **S1400 Local Pathology Review Form:**
 - Tumor material must be reviewed by a local pathologist to ensure sufficient tumor cells are present in the sample. The local pathologist must review and sign off on the **S1400** Local Pathology Review form noting that the tumor tissue contains at least 20% viable tumor cells.

S1400 Registration and Sub-study Assignment

Screen for eligibility, consent patient and confirm that required amount of tissue is available for submission

(pathologist to complete the Local Pathology Review Form)



Register to S1400 in OPEN



Submit tissue specimen within 1 day after registration

(Ship to FMI and log shipment using the Specimen Tracking System)



Within 16 days after S1400 registration



**Site staff receives email from SWOG with sub-study assignment
(Assignment will also display in the Sub-study Assignment form in Rave®)**

Post Sub-study Assignment – Patient Eligible

Evaluate common eligibility and sub-study specific eligibility criteria



If patient IS eligible for assigned sub-study



Register to sub-study in OPEN within 42 days of receiving sub-study assignment email to receive randomized sub-study treatment assignment



Administer protocol treatment within 7 working days of sub-study registration, conduct follow-up, obtain and submit specimens and forms per sub-study protocol

Post Sub-study Assignment – Patient Ineligible for Sub-study

Evaluate common eligibility and sub-study specific eligibility criteria



If patient is assigned to S1400 B, C, D, or E, meets common eligibility but does NOT meet study-specific eligibility criteria



Submit Request for Sub-study Reassignment form in Rave®



Site staff receives email with new sub-study assignment
(Timing and process same)

Post Sub-study Assignment – Patient Ineligible

Evaluate common eligibility and sub-study specific eligibility criteria



**If patient is NOT eligible for the common sub-study criteria
OR assigned to S1400A and does NOT meet S1400A eligibility
criteria**



Submit *Notice of Intention not to Register* form in Rave®



Follow and submit required forms until 3 years from registration or death
(whichever comes first) per S1400 protocol

Funding Highlights

- Sites will receive up to \$5,869 (\$1,079 screening/\$4,790 registration) for each patient on trial
- If biopsies are needed, sites will receive \$3,000/\$6,000 for the biopsies performed at screening and/or progression after initial response on Arm 1
- Sites will be reimbursed for additional research based procedures
- Sites will be reimbursed \$1,333 for extra audit visits outside regular schedule

Funding Changes

FDA has requested tests/procedures to be performed on the investigational and standard-of-care arms. Sites will be reimbursed for the following additional procedures on both arms.

Sub-study	Additional Funding for Procedure/Test
S1400A	TSH T3/T4*
S1400B	HbA1c, Lipase, Amylase
S1400C	EKG, HbA1c*
S1400D	OCT Scan, Ophthalmological Assessment, MUGA, Phosphate, Urinalysis, Troponin
S1400E	No changes
*This is an added test requested by the Company as part of the amendment	

